Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141861 | 0.91 | TDO2 (0.32) | TDO2CTSAAKR1C3AKR1C2CNR1 | |
| SCHEMBL17301180 | 0.85 | RXRB (0.30) | — | |
| SCHEMBL15809350 | 0.85 | RXRB (0.30) | — | |
| SCHEMBL15827920 | 0.85 | HTT (0.36) | CNR1CNR2 | |
| SCHEMBL17301181 | 0.81 | RXRB (0.30) | — | |
| SCHEMBL15809148 | 0.81 | RXRB (0.30) | — | |
| SCHEMBL15809253 | 0.80 | TDO2 (0.32) | TDO2CTSAKMT2A | |
| SCHEMBL15809030 | 0.80 | TDO2 (0.32) | TDO2CTSA | |
| SCHEMBL18772556 | 0.79 | AKR1C3 (0.30) | AKR1C3AKR1C2CNR1CNR2NR1I2 | |
| SCHEMBL15821440 | 0.79 | AKR1C3 (0.31) | AKR1C3AKR1C2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2746301-B1 | Catalyst | BOREALIS AG (AT) | 2018-05-30 | — | — | EP | disclosed |
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9598517-B2 | Catalysts | BOREALIS AG (AT) | 2017-03-21 | — | — | US | disclosed |
| US-9598517-B2 | Catalysts | BOREALIS AG (AT) | 2017-03-21 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-20150344596-A1 | CATALYSTS | BOREALIS AG (AT) | 2015-12-03 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| WO-2014096166-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-06-26 | — | — | WO | disclosed |
| EP-2746301-A1 | Catalyst | Borealis AG (AT) | 2014-06-25 | — | — | EP | disclosed |
| EP-2729479-A1 | CATALYSTS | Borealis AG (AT) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013007650-A1 | CATALYSTS | BOREALIS AG (AT) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024123-A1 | Asymmetrical Ligands | CCRL2, AR, CCR2 | TDO2 1604/4885CTSA 4066/4885AKR1C3 198/4885 |
| US-20150344596-A1 | CATALYSTS | SFN, AP3S1, H1-2 | TDO2 1206/4885CTSA 4149/4885AKR1C3 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.